Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Ohio Appellate Court Rules in Favor of Gender-Affirming Care

Client Alert

On Tuesday, March 18, 2025, the 10th District Court of Appeals in Franklin County ruled that House Bill (HB) 68’s restrictions on the provision of puberty blockers and hormones to minors seeking gender-affirming care violates the Health Care Freedom Amendment to the Ohio Constitution and therefore, are not enforceable in Ohio.

According to the 10th District, banning prescription drugs (including puberty blockers and hormones) interferes with parents’ rights to care for their children and prohibits parents from accessing for their minor children and deciding on medical treatment that follows the standards of care and professional guidelines accepted in the medical community to treat gender-related conditions.

The case, Moe v. Yost, has been remanded back to the Franklin County Court of Common Pleas. Ohio Attorney General Dave Yost has explicitly indicated that his office will appeal the ruling.

HB 68 became effective in August 2024 and broadly, prevents minors from accessing gender-affirming care (including hormone blockers, hormone replacement therapy (HRT), and some mental health services) without first being assessed for other comorbidities, including depression, anxiety, ADHD, and autism spectrum disorder, as well as for signs of physical, sexual, mental, or emotional abuse, and other traumas.

BMD previously drafted a client alert on HB 68, available here.

If you have any questions regarding this ruling, or HB 68 generally, please contact BMD Healthcare Member Daphne Kackloudis at dlkackloudis@bmdllc.com or Attorney Jordan Burdick at jaburdick@bmdllc.com.


Ohio Medicaid Extends Timely Filing Deadline Until 2025

The Ohio Department of Medicaid (ODM) recently announced that it is extending its timely filing deadline to February 28, 2025. According to ODM, roughly 2% of providers have contract issues preventing them from meeting the previous timely filing deadline of December 1, 2024.

Another Drug Manufacturer Pursues Rebate Program as 340B Alternative

Some of the nation’s largest drug manufacturers are forging ahead to implement rebate programs for 340B drugs, even after the federal government has called these programs illegal. While it is unclear how these federal courts will rule, this could threaten the sustainability of safety net providers and their patients.

Hurry Up, STOP. . .Has CTA Been Struck Down By Courts?

Following a recent case in Texas, uncertainty has arisen regarding whether clients should file "beneficial owners" reports. This is a result of the Federal Government enjoined from enforcing the CTA. Contact your BMD Member Blake Gerney to find out how this affects you.

DEA and HHS Issue its Third Extension of Telemedicine Flexibilities through 2025

The DEA and U.S. Department of Health and Human Services (HHS) have extended telemedicine flexibilities for prescribing controlled medications through December 31, 2025. This extension builds on temporary exceptions made in 2020 due to COVID-19, allowing providers to prescribe Schedule II-V controlled substances based on a telemedicine evaluation alone. The extension ensures continued patient access to necessary prescriptions and provides time for providers to comply with future regulations.

Medicare Making Changes to Improve Behavioral Health Care Access

The Centers for Medicare & Medicaid Services (CMS) has introduced changes to Medicare’s behavioral health coverage, including allowing Marriage and Family Therapists and Mental Health Counselors to enroll independently, increasing reimbursements for crisis psychotherapy and substance use treatment, and expanding services via community health workers. These updates address gaps in care and improve access to mental health services for Medicare beneficiaries.